Savage Patrick, Campbell Michael, Hogg Meadhbh, McElhatton Daniel, Menown Ian
Craigavon Cardiology Department, Southern Health & Social Care Trust, Craigavon, Northern Ireland, UK.
Queens University Belfast, Queens University Belfast, Belfast, United Kingdom.
Adv Ther. 2025 May 19. doi: 10.1007/s12325-025-03220-9.
In 2024, numerous key clinical trials in the field of clinical cardiology have been published or presented at major international conferences. This review seeks to collate and summarise these trials and reflect on their clinical context.
The authors evaluated all clinical trials presented at major cardiology conferences during 2024 with a focus on clinical trials which would influence and/or change current clinical practice. We reviewed clinical trials presented at all major international conferences including the American College of Cardiology (ACC), European Association for Percutaneous Cardiovascular Interventions (EuroPCR), European Society of Cardiology (ESC), Transcatheter Cardiovascular Therapeutics (TCT), American Heart Association (AHA), European Heart Rhythm Association (EHRA), Society for Cardiovascular Angiography and Interventions (SCAI), TVT-The Heart Summit (TVT) and Cardiovascular Research Technologies (CRT). Trials considered to have highest impact and/or broad relevance across the field of clinical cardiology, with a high likelihood to change or impact upon clinical practice were included.
Over 90 key cardiology clinical trials were identified across the spectrum of clinical cardiology. Important updates in percutaneous coronary intervention were reviewed including new ESC guidance and several key trials in the field of coronary physiology (FAVOR III), drug-coated balloons (REGCAGE-FREE, AGENT-IDE), shock, and acute coronary syndromes (SENIOR-RITA, DanGer-Shock). Structural trials included major updates in transcatheter aortic valve replacement (TAVR) from EARLY-TAVR, TAVR-UNLOAD and NOTION 3, as well as seminal trials in tricuspid (TRISCEND II) and mitral intervention (MATTERHORN). Key updates in preventative cardiology included new data in lipoprotein (a) pharmacotherapy, low-density lipoprotein (LDL) cholesterol reduction and hypertension management (BPROAD, BedMed, KRAKEN), as well as several key trials in heart failure (SUMMIT, FINEARTS) hypertrophic cardiomyopathy (SEQUOIA-HCM) and cardiac amyloid (HELIOS-B).
The review presents a concise summary of the key clinical cardiology trials published or presented during the past year and should be of interest to clinicians and researchers in the field of cardiology.
2024年，临床心脏病学领域有众多关键临床试验在主要国际会议上发表或展示。本综述旨在整理和总结这些试验，并思考其临床背景。
作者评估了2024年在主要心脏病学会议上展示的所有临床试验，重点关注那些会影响和/或改变当前临床实践的试验。我们回顾了在所有主要国际会议上展示的临床试验，包括美国心脏病学会（ACC）、欧洲经皮心血管介入协会（EuroPCR）、欧洲心脏病学会（ESC）、经导管心血管治疗学术会议（TCT）、美国心脏协会（AHA）、欧洲心律协会（EHRA）、心血管造影和介入学会（SCAI）、TVT心脏峰会（TVT）以及心血管研究技术会议（CRT）。纳入了那些在临床心脏病学领域被认为具有最高影响力和/或广泛相关性、极有可能改变或影响临床实践的试验。
在整个临床心脏病学领域共确定了90多项关键心脏病学临床试验。回顾了经皮冠状动脉介入治疗的重要进展，包括新的ESC指南以及冠状动脉生理学领域（FAVOR III）、药物涂层球囊（REGCAGE-FREE、AGENT-IDE）、休克和急性冠状动脉综合征（SENIOR-RITA、DanGer-Shock）的多项关键试验。结构性试验包括来自EARLY-TAVR、TAVR-UNLOAD和NOTION 3的经导管主动脉瓣置换术（TAVR）的重大进展，以及三尖瓣（TRISCEND II）和二尖瓣介入（MATTERHORN）的开创性试验。预防心脏病学的关键进展包括脂蛋白（a）药物治疗、低密度脂蛋白（LDL）胆固醇降低和高血压管理（BPROAD、BedMed、KRAKEN）的新数据，以及心力衰竭（SUMMIT、FINEARTS）、肥厚型心肌病（SEQUOIA-HCM）和心脏淀粉样变（HELIOS-B）的多项关键试验。
本综述简要总结了过去一年发表或展示的关键临床心脏病学试验，心脏病学领域的临床医生和研究人员应会对此感兴趣。
